KalVista Q1 net loss $23.0M ($0.94/share); cash $142.1M, down $24.1M from April

KalVista Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.94

No revenue; R&D spending rose to $18.2M (vs. $13.7M a year ago), driven by Phase 3 KONFIDENT and preclinical costs.
Net loss widened to $23.0M from $16.1M; cash burn reflects higher operating expenses.
KVD824 Phase 2 KOMPLETE trial passed 50% enrollment; top-line data expected mid-2023.
Open-label extension (KONFIDENT-S) initiated for sebetralstat; Phase 3 KONFIDENT data expected H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.